What is ILMN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 42.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ILMN?

P/E (TTM) is 50.91 and 52-week range is $88.00 to $309.35 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ILMN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ILMN?

The company profile lists revenue (TTM) near $4.44B, net income (TTM) near $816M, EPS (TTM) near $5.38 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Illumina Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 151.3M shares outstanding, ISIN US4523271090 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Illumina Inc

$ILMN

Health Care · Life Sciences Tools & Services

IR Run Scenarios

$278.17

+5.14%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,600 full-time employees. The company went IPO on 2000-06-28. The firm's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. The company also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.

Employees

8,625

Website

www.illumina.com

IPO

2000-06-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)